cas 22715-27-1|| where to buy 2,5-Diaminepyrimidine

Nom du produit:2,5-Diaminepyrimidine

IUPAC Name:pyrimidine-2,5-diamine

Unité d'emballage	Stock disponible	Prix($)
CM167296-250mg	in stock	ŮǪ
CM167296-1g	in stock	ħƚǸ
CM167296-5g	in stock	ŮŌƴ
CM167296-25g	in stock	ħǪŤƚ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 22715-27-1 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:22715-27-1; Formule moléculaire:C4H6N4; Point de fusion:-; Code SMILES:C1=C(N)C=NC(=N1)N; Densité:

: Numéro de catalogue:CM167296; Poids moléculaire:110.12; Point d'ébullition:; N° Mdl:MFCD00129726; Stockage:Store at 2-8°C.

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: STX-478; Scorpion presented initial, first-in-human clinical results from its Phase 1/2 study of STX-478 in advanced solid tumor patients in a Proffered Paper late-breaking session at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain. Initial Phase 1 monotherapy data for STX-478, an oral, once-daily, mutant-selective, allosteric PI3Kα inhibitor, demonstrated potentially best-in-class PI3Kα inhibition, with anti-tumor activity observed in multiple cancer types, including HR+/HER2- breast cancer (BC), gynecological tumors, and other solid tumors. STX-478 was well-tolerated, including in pre-diabetic, diabetic and heavily pre-treated patients and showed no significant wild-type-mediated toxicities.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.